Security
Oncolytics Biotech, Inc. Common Shares · ONCY
ONCYNASDAQCommon stockCurrentCIK 1129928Updated Oct 14, 2026
ONCY price & chart
Loading TradingView…
NASDAQ:ONCY on TradingView ↗About the company
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
In the news
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer ↗
Smart Oncology: 5 Stocks Chasing the $317B Prize News provided by USA News Group Dec 31, 2025, 07:25 ET Share this article Share to X Share this article Share to X Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC , Dec. 31, 2025 /PRNewswire/ -- The precisio ↗
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada News provided by Oncolytics Biotech® Inc. Oct 20, 2025, 09:00 ET Share this article Share to X Share this article Share to X SAN DIEGO , Oct. 20, 2025 /PRNewswire/ -- O ↗
Recent filings
Other Events
Items 8.01
DEFA14A filing
DEF 14A filing
Other Events
Items 8.01
Other Events
Items 8.01
Show 5 more recent filings
Other Events
Items 8.01
Other Events
Items 8.01
10-Q filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,582,000Source | 20,187,000Source | 38,820,000Source | 37,334,000Source |
| Property, Plant and Equipment, NetUSD | 228,000Source | 286,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,202,000Source | — | — | — |
| Assets, CurrentUSD | 6,844,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | 510,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,381,000Source | 14,204,000Source | 11,257,000Source | 10,832,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 0Source | — | — | — |
| Additional Paid in CapitalUSD | 419,471,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -429,495,000Source | — | — | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 6,225,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | -3,799,000Source | — | — | — |
| Liabilities and EquityUSD | 7,582,000Source | — | — | — |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,101,000Source | — | — | — |
| Operating Lease, Liability, CurrentUSD | 193,000Source | — | — | — |
| Accounts Payable, CurrentUSD | 3,504,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 370,000Source | — | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,327,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | — | — | — |
| IssuedCapitalCAD | — | 438,193,000Source | 430,906,000Source | 404,040,000Source |
| TradeAndOtherCurrentPayablesCAD | — | 4,792,000Source | 3,572,000Source | 3,650,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | — | -31,710,000Source | -27,752,000Source | -24,835,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,104,000Source | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 2,932,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -20,112,000Source | — | — | — |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -6,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,000Source | — | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,120,000Source | — | — | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -27,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,877,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,202,000Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 67,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 121,000Source | — | — | — |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsCAD | — | 2,723,000Source | 1,917,000Source | 2,378,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | — | -838,000Source | 282,000Source | -1,625,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 6,571,000Source | — | — | — |
| DepreciationUSD | 70,000Source | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | -388,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -106,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 137,000Source | — | — | — |
| General and Administrative ExpenseUSD | 15,411,000Source | 13,335,000Source | 16,082,000Source | 11,492,000Source |
| Income Tax Expense (Benefit)USD | 79,000Source | — | — | — |
| IncreaseDecreaseInWorkingCapitalCAD | — | -3,538,000Source | -1,765,000Source | -391,000Source |
| Investment Income, InterestUSD | 386,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -28,759,000Source | — | — | — |
| Operating ExpensesUSD | 28,725,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 45,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 32,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -28,725,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 45,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -28,680,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 79,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -28,759,000Source | — | — | — |
| Earnings Per Share, BasicUSD per share | -0.3Source | — | — | — |
| Earnings Per Share, DilutedUSD per share | -0.3Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 95,857,147Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 95,857,147Source | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareCAD/shares | — | -0.41Source | -0.41Source | -0.43Source |
| Current Income Tax Expense (Benefit)USD | 79,000Source | — | — | — |
| CurrentTaxExpenseIncomeCAD | — | — | 97,000Source | 84,000Source |
| DepreciationRightofuseAssetsCAD | — | 304,000Source | 322,000Source | 299,000Source |
| DilutedEarningsLossPerShareCAD/shares | — | -0.41Source | -0.41Source | -0.43Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | -388,000Source | — | — | — |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCAD | — | 2,723,000Source | 1,917,000Source | 2,378,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -106,000Source | — | — | — |
| General and Administrative ExpenseUSD | 15,411,000Source | 13,335,000Source | 16,082,000Source | 11,492,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -15,605,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsCAD | — | 130,000Source | 97,000Source | 84,000Source |
| InterestExpenseOnLeaseLiabilitiesCAD | — | 139,000Source | 71,000Source | 80,000Source |
| Investment Income, InterestUSD | 386,000Source | — | — | — |
| Operating ExpensesUSD | 28,725,000Source | — | — | — |
| ProfitLossBeforeTaxCAD | — | -31,580,000Source | -27,655,000Source | -24,751,000Source |
| ProfitLossFromOperatingActivitiesCAD | — | -34,982,000Source | -33,791,000Source | -26,924,000Source |
| Research and Development ExpenseUSD | 13,314,000Source | 21,647,000Source | 17,709,000Source | 15,432,000Source |
Offerings
Registration 333-289819
Registration 333-294811
Registration 333-290954
Filing attachments
tm2610715d1_ex99-2.htm · 8-K · 2026-04-01
EX-99.2 3 tm2610715d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Oncolytics Biotech ® Completes Domicile Change to the United States SAN DIEGO, CA, April 1, 2026 - Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States (…
Read attachment ↗tm2610569d2_ex4-2.htm · S-8 · 2026-04-01
Exhibit 4.2 ARTICLES OF INCORPORATION OF ONCOLYTICS BIOTECH INC. ARTICLE I name The name of the Corporation is Oncolytics Biotech Inc. (the “Corporation”). ARTICLE II registered office and registered agent The registered office of the Corporation shall be the street address of its registered agent in the State of Nevada. The Corporation may, from time to time, in the manner provided by law, change the registered agent and registered office within the State of Nevada. The Corporation may als…
Read attachment ↗tm2610569d2_ex4-3.htm · S-8 · 2026-04-01
Exhibit 4.3 BYLAWS of ONCOLYTICS BIOTECH INC. a Nevada corporation Article I OFFICES Section 1.1 Principal Office. The principal office and place of business of Oncolytics Biotech Inc. (the “ Corporation ”) shall be at such location as is established from time to time by resolution of the board of directors of the Corporation (the “ Board of Directors ”). Section 1.2 Other Offices. Other offices and places of business either within or without the State of Nevad…
Read attachment ↗tm2610569d2_ex99-1.htm · S-8 · 2026-04-01
Exhibit 99.1 ONCOLYTICS BIOTECH INC. 2026 Incentive Award Plan ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. Eligibility Service Providers are eligible to be grant…
Read attachment ↗ex41-descriptionofsecuriti.htm · 10-K · 2026-03-30
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description sets forth certain material terms and provisions of the securities of Oncolytics Biotech Inc. (“we,” “us” or “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. The following description of our securities is not complete and may not contain all the information you should consider before investing in our securities. This description is summarized from, and qualified in its entiret…
Read attachment ↗